Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

60.10
+1.763.01%
Post-market: 60.100.00000.00%16:18 EDT
Volume:9K
Turnover:529.71K
Market Cap:95.56M
PE:- -
High:60.30
Open:59.41
Low:59.41
Close:58.34
52wk High:64.60
52wk Low:42.76
Shares:1.59M
Float Shares:1.59M
Volume Ratio:1.13
T/O Rate:0.55%
Dividend:0.63
Dividend Rate:1.05%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

What Eli Lilly Stock's First Line Jaypirca Approval Means For Shareholders

Simply Wall St.
·
Oct 07

Halozyme Therapeutics Shares up 2% After Court Win Against Merck to Block Subcutaneous Keytruda in Select Markets

THOMSON REUTERS
·
Oct 07

Micro-Cap Stock Veraxa Biotech is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Dow Jones
·
Oct 07

Morgan Stanley Adjusts Price Target on Merck to $177 From $179

MT Newswires Live
·
Oct 07

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

TIPRANKS
·
Oct 07

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Oct 07

Halozyme announces Dutch court of the Hague found Merck infringed patents

TIPRANKS
·
Oct 07

AbbVie Says FDA Grants Breakthrough Therapy Status for ABBV-400 in Metastatic Colorectal Cancer

Reuters
·
Oct 07

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Oct 07

Abbvie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations from the U.S. FDA for Crc and Nsclc

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Iv Version of Keytruda Remains Available and not Covered by Halozyme's Patent or Court Injunction

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Rejects Merck's Arguments That Ep622 Patent is Invalid

THOMSON REUTERS
·
Oct 07

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda Sc in Multiple European Markets

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Court Orders Msd BV to Stop Keytruda Sc Manufacture and Sale in Eight European Countries

THOMSON REUTERS
·
Oct 07

Halozyme Therapeutics - Injunction Forbids Msd from Facilitating Infringement by Affiliates

THOMSON REUTERS
·
Oct 07

Tempus Announces Multi-Year Collaboration with Moderna and Merck

THOMSON REUTERS
·
Oct 07

Morgan Stanley Adjusts Price Target on Eli Lilly to $1,430 From $1,419

MT Newswires Live
·
Oct 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 07

Rox Resources Issues New Batch of Unquoted Performance Rights

TIPRANKS
·
Oct 07

Rox Resources Seeks ASX Quotation for Employee Incentive Shares

TIPRANKS
·
Oct 07